Abstract
Background: Patients with congestive heart failure (CHF) have alterations in the traditional and nonlinear indices of heart rate (HR) dynamics, which have been associated with an increased risk of mortality. This study was designed to test the effects of carvedilol, a nonselective beta‐blocker with alpha‐1 blocking properties, on HR dynamics in patients with CHF.
Methods: We studied 15 patients with CHF secondary to ischemic or idiopathic cardiomyopathy who met the following inclusion criteria: NYHA functional class II‐III, optimal conventional medical therapy, normal sinus rhythm, left ventricular ejection fraction (LVEF) of < 40%, and resting systolic blood pressure greater than 100 mmHg. The 6‐minute corridor walk test, estimation of LVEF, and 24‐hour Holter recording were performed at baseline and after 12 weeks of therapy with carvedilol. Traditional time and frequency domain measures and short‐term fractal scaling exponent of HR dynamics were analyzed.
Results: After 12 weeks of therapy with carvedilol, the mean LVEF improved significantly (from 0.27 ± 0.08 to 0.38 ± 0.08, P < 0.001). The average HR decreased significantly (from 86 ± 11 to 70 ± 8 beats/min, P < 0.001). The mean distance traveled in the 6‐minute walk test increased significantly (from 177 ± 44 to 273 ± 55 m, P < 0.01). The frequency‐domain indices (HF and LF), the time domain indices (rMSSD and PNN5), and the short‐term fractal scaling exponent increased significantly. The scaling exponent increased particularly among the patients with the lowest initial values (< 1.0), and the change in the fractal scaling exponent correlated with the change in ejection fraction (r = 0.63, P < 0.01).
Conclusion: Carvedilol improves time and frequency domain indices of HR variability and corrects the altered scaling properties of HR dynamics in patients with CHF. It also improves LVEF and functional capacity. These specific changes in HR behavior caused by carvedilol treatment may reflect the normalization of impaired cardiovascular neural regulation of patients with CHF. A.N.E. 2002;7(2):133–138
Keywords: carvedilol, heart rate variability, congestive heart failure
REFERENCES
- 1. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK‐Heart). Circulation 1998;98: 1510–1516. [DOI] [PubMed] [Google Scholar]
- 2. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79:1645–1650. [DOI] [PubMed] [Google Scholar]
- 3. Ho KKL, Moody GB, Peng CK, et al. Predicting survival in heart failure cases and controls using fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. Circulation 1997;96:842–848. [DOI] [PubMed] [Google Scholar]
- 4. Huikuri HV, Mäkikallio TH, Peng CK, et al. for the DIAMOND Study Group. Fractal correlation properties of R‐R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. Circulation 2000;101: 47–54. [DOI] [PubMed] [Google Scholar]
- 5. Niemelä MJ, Airaksinen KEJ, Huikuri HV. Effect of beta‐blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994;23:1370–1377. [DOI] [PubMed] [Google Scholar]
- 6. Sandrone G, Mortrara A, Torzillo D, et al. Effects of beta‐blockers(atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994;74:340–345. [DOI] [PubMed] [Google Scholar]
- 7. Keeley EC, Page RL, Lange RA, et al. Influence of metoprolol on heart rate variability in survivors of remote myocardial infarction. Am J Cardiol 1996;77:557–560. [DOI] [PubMed] [Google Scholar]
- 8. Lin LY, Lin JL, Du CC, et al. Reversal of deteriorated fractal behavior of heart rate variability by beta‐blocker therapy in patients with advanced congestive heart failure. J Cardio-vasc Electrophysiol 2001;12:26–32. [DOI] [PubMed] [Google Scholar]
- 9. Packer M, Bristow MR, Cohn J, et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Eng J Med 1996;334: 1349–1355. [DOI] [PubMed] [Google Scholar]
- 10. Morata A, La Rovere MT, Pinna GD, et al. Nonselective beta‐adrenergic blocking agent, carvedilol, improves arterial baroreflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000;36:1612–1618. [DOI] [PubMed] [Google Scholar]
- 11. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93: 1043–1065. [PubMed] [Google Scholar]
- 12. Peng CK, Havlin S, Stanley HE, et al. Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. Chaos 1995;5:82–87. [DOI] [PubMed] [Google Scholar]
- 13. Ivengar N, Peng C‐K, Morin R, et al. Age‐related alterations in the fractal scaling of cardiac interbeat interval dynamics. Am J Physiol 1996;271:R1078–R1084. [DOI] [PubMed] [Google Scholar]
- 14. Makikallio TH, Seppanen T, Airaksinen KEJ, et al. Dynamic analysis of heart rate may predict subsequent ventricular tachycardia after myocardial infarction. Am J Cardiol 1997;80:779–783. [DOI] [PubMed] [Google Scholar]
- 15. van de Borne P, Montano N, Pagani M, et al. Absence of low‐frequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997;95:1449–1454. [DOI] [PubMed] [Google Scholar]
- 16. Mäkikallio TH, Huikuri HV, Hintze U, et al. Fractal analysis and time and frequency domain measures of heart rate variability as predictors of mortality in patients with heart failure. Am J Cardiol 2001;87:178–182. [DOI] [PubMed] [Google Scholar]
- 17. Tulppo MP, Mäkikallio TH, Seppänen T, et al. Heart rate dynamics during accentuated sympathovagal interaction. Am J Physiol 1998;274:H810–H816. [DOI] [PubMed] [Google Scholar]
- 18. Bristow M, Gilbert EM, Abraham WT, et al. for the MOCHA Investigators. Carvedilol produces dose‐related improvement in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94: 2807–2816. [DOI] [PubMed] [Google Scholar]
- 19. Sanderson JE, Chan SKW, Yip G, et al. Beta‐blockade in heart failure: A comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522–1528. [DOI] [PubMed] [Google Scholar]
- 20. Wisenbaugh T, Katz I, Davis J, et al. Long‐term (3‐month) effects of a new beta‐blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21: 1094–1100. [DOI] [PubMed] [Google Scholar]
- 21. Flapan AD, Nolan J, Neilson JMM, et al. Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 1992;69:532–535. [DOI] [PubMed] [Google Scholar]
- 22. Zhang YH, Song YC, Zhu J, et al. Effects of enalapril on heart rate variability in patients with congestive heart failure. Am J Cardiol. 1995;76: 1045–1048. [DOI] [PubMed] [Google Scholar]
- 23. Korkmaz ME, Muderrisoglu H, Ulucam M, et al. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 2000;86:649–653. [DOI] [PubMed] [Google Scholar]
- 24. Vardas PE, Kanoupakis EM, Kochiadakis GE, et al. Effects of long‐term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure. Cardiovasc Drugs Ther 1998;12:47–55. [DOI] [PubMed] [Google Scholar]
- 25. Lopera G, Huikuri HV, Mäkikallio TH, et al. Is abnormal heart rate variability a specific feature of congestive heart failure Am J Cardiol 2001;87:1211–1213. [DOI] [PubMed] [Google Scholar]